# T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

> **NCT07683754** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Metastatic Breast Cancer
- HER2 Positive
- HR Positive

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Endocrine Therapy
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT07683754
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-04
- **Primary completion:** 2030-07-04
- **Final completion:** 2030-08-28
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683754, "T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*